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1  | INTRODUC TION
MicroRNAs (miRs) are small non‐coding RNAs that play an import‐
ant role in gene regulation.1‐3 In the nucleus primary miRs are tran‐
scribed by Ribonucleic acid (RNA) polymerases and then cleaved 
into double‐stranded miR precursors (Pre‐miRs) by RNase III en‐
zyme (Drosha) and DiGeorge syndrome critical region 8 (DGCR8).1,2 
Pre‐miRs are exported into the cytoplasm where they are further 
cleaved into a guide strand and a passenger strand by the enzyme 
Dicer. Then the guide strand is loaded onto the RISC that binds to 
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Abstract
MicroRNAs (miRs) are small non‐coding RNAs that regulate gene expression in physi‐
ological processes as well as in diseases. Currently miRs are already used to find novel 
mechanisms involved in diseases and in the future, they might serve as diagnostic 
markers. To identify miRs that play a role in glomerular diseases urinary miR‐screen‐
ings are a frequently used tool. However, miRs that are detected in the urine might 
simply be filtered from the blood stream and could have been produced anywhere in 
the	body,	so	they	might	be	completely	unrelated	to	the	diseases.	We	performed	a	
combined miR‐screening in pooled urine samples from patients with different glo‐
merular diseases as well as in cultured human podocytes, human mesangial cells, 
human glomerular endothelial cells and human tubular cells. The miR‐screening in 
renal	 cells	 was	 done	 in	 untreated	 conditions	 and	 after	 stimulation	with	 TGF‐β. A 
merge of the detected regulated miRs led us to identify disease‐specific, cell type‐
specific and cell stress‐induced miRs. Most miRs were down‐regulated following the 
stimulation	with	TGF‐β	 in	all	cell	types.	Up‐regulation	of	miRs	after	TGF‐β was cell 
type‐specific	for	most	miRs.	Furthermore,	urinary	miRs	from	patients	with	different	
glomerular diseases could be assigned to the different renal cell types. Most miRs 
were specifically regulated in one disease. Only miR‐155 was up‐regulated in all dis‐
ease urines compared to control and therefore seems to be rather unspecific. In con‐
clusion, a combined urinary and cell miR‐screening can improve the interpretation of 
screening results. These data are useful to identify novel miRs potentially involved in 
glomerular diseases.
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the	3′	untranslated	region	(3′UTR)	of	a	target	messenger	RNA	and	
inhibits RNA translation.4 Several miRs are enriched in human kid‐
ney and miRs seem to play a role in the glomerular homeostasis.5 
Mice with podocyte‐specific alteration in miR‐expression by dele‐
tion of Dicer or Drosha display progressive glomerular damage with 
proteinuria and podocyte defects.6,7 MiRs can be secreted in body 
fluids and therefore could possibly serve as biomarkers in various 
glomerular	 diseases.	 For	 example,	 patients	 with	 focal	 segmental	
glomerulosclerosis	 (FSGS)	 had	 10‐times	 elevated	 concentrations	
of miR‐3d and miR‐10a in the urine compared to healthy controls.8 
Urinary	expression	of	miR‐200a,	miR‐200b	and	miR‐429	were	down‐
regulated in patients with IgA glomerulonephritis (IgA‐GN) and this 
down‐regulation correlated with severity of the disease and rate 
of progression.9 MiRs offer some important advantages over other 
markers as they are stable and protected from endogenous RNase 
because of their small size and by packaging within exosomes.10,11 
However, although suggested as potential biomarkers the origin of 
miRs has rarely been defined and cell type specific miRs have not 
yet been reported in the kidney. In the past miR‐screenings in body 
fluids or tissue samples of patients with glomerular diseases were 
compared to healthy controls.12‐14 By this approach, comparing sam‐
ples of one disease to control samples makes the specificity of the 
findings elusive. In addition, it is not clear if the miRs are ‘bystand‐
ers’ or might originate from cells and tissues involved in the disease. 
Urinary	miRs	might	be	filtered	from	the	blood,	excreted	by	tubular	
cells or derived directly from glomerular cells affected by the disease 
process.
In this study, we described the advantages of a combined miR‐
screening in urine as well as in cultured renal cells and explained 
different	ways	of	 data	normalization	 and	 interpretation.	We	 iden‐
tified renal cell type‐specific miRs and miRs specifically regulated 
by	TGF‐β in these cells. Hereby, we were able to investigate miRs in 
urines from patients with different glomerular diseases and could 
compare them to controls. In addition, we could assign the urinary 
miRs to the different renal cell types.
2  | MATERIAL S AND METHODS
2.1 | Cell culture
Under	permissive	conditions	at	33°C,	podocytes	proliferate.	When	
cultured	 at	 37°C,	 the	SV40	T‐antigen	was	 inactivated	 for	 cell	 dif‐
ferentiation. Culture medium for human podocytes was RPMI 
1640 Medium (Roth, Karlsruhe, Germany) with 10% foetal calf 
serum	 (FCS;	PAA	Laboratories,	Pasching,	Australia),	1%	Penicillin/
Streptomycin and 0.1% Insulin. Human proximal tubular cells 
were cultured with renal epithelial cell media (Promocell, Baden‐
Württemberg,	Germany)	with	5%	FCS	(PAA	Laboratories,	Pasching,	
Australia), 10 ng/mL recombinant human epidermal growth factor, 
5 μg/mL recombinant human Insulin, 0.5 μg/mL Epinephrine, 36 ng/
mL Hydrocortisone, 5 μg/mL Transferrin and 4 pg/mL Triiodo‐L‐thy‐
ronine. Human glomerular endothelial cells (Clonetech, Mountain 
View,	CA)	were	 cultured	 in	 endothelial	 cell	 basal	media	 (EBM™‐2; 
CC‐3156,	Lonza;	Fisher).	This	medium	was	added	with	endothelial	
cell	growth	medium	that	contains	0.1%	hEGF,	0.1%	hydrocortison,	
0.4%	hFGF‐b,	0.1%	VEGF,	0.1%	R3‐IGF‐1,	0.1%	Ascorbic	Acid,	0.1%	
Heparin,	 2%	 FBS	 and	 0.1%	GA.	Human	mesangial	 cells	were	 cul‐
tured in Dulbecco's Modified Eagles's medium supplemented with 
10%	FCS	and	1%	Penicillin‐Streptomycin.	Culture	Conditions	were	
37°C	and	5%	CO2 air atmosphere. Cells were stimulated with 5 ng/
mL	human	TGF‐β1 (Sigma Aldrich, Darmstadt, Germany) or high glu‐
cose (50 nmol/L). Cells were harvested 48 hours later with Quiazol 
for	 RNA	 isolation	 Urine	 sample	 preparation	 for	 miR‐screening.	
Morning urine was collected from healthy volunteers and from pa‐
tients	with	biopsy‐proven	glomerular	diseases:	FSGS,	membranous	
glomerulonephritis (MGN), membranoproliferative glomerulone‐
phritis (MPGN), diabetic nephropathy (DN), minimal change dis‐
ease (MCD), preeclampsia (PREEC), haemolytic uraemic syndrome 
(HUS)	 and	 IgA‐glomerulonephritis	 (IgA‐GN).	 Ethical	 approval	 was	
obtained from Ethics Committee of the Hanover Medical School 
(#1709‐2013).	In	total	36	patients	were	included	in	the	study.	Urine	
F I G U R E  1   MiR‐screening in renal cell types and urines from patients with different glomerular diseases. Illustration of miR‐screening 
setup in cultured renal cell types and in urine samples of patients with different glomerular diseases. MiR‐screenings were done with 
TaqMan®	Array	Human	MicroRNA	Card	Set	v3.0.	Cells	were	left	either	untreated	or	stimulated	with	TGF‐β for 48 h. DN, diabetic 
nephropathy;	FSGS,	focal	segmental	glomerulosclerosis;	HUS,	haemolytic	uraemic	syndrome;	IgA‐GN,	IgA‐glomerulonephritis;	MCD,	
minimal change disease; MGN, membranous glomerulonephritis; MPGN, membranoproliferative glomerulonephritis; PREEC, preeclampsia
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samples (50 mL) were centrifuged at 75455 g for 15 minutes to pel‐
let the cells and cellular debris. The cell‐free urine supernatant was 
stored	at	−80°C	until	miR‐screening	analysis.	Pooled	urine	samples	
from four patients per disease were used in the miR‐screening.
2.2 | MiR‐isolation and miR‐screening
Purification of total RNAs including miRs from cultured renal cells 
and cell‐free urine from patients was done with miRNeasy Kit 
(QIAGEN,	Venlo,	Netherlands).	QIAzol	 lysis	 reagent	was	 added	 to	
the	samples,	mixed	and	incubated	for	5	minutes.	Five	microlitres	μL 
of 5 nmol/L Syn‐cel‐miR‐39 was added to each urinary sample to 
control for variations during preparation and later normalization for 
endogenous miRs. Chloroform was added to the samples, they were 
centrifuged and the upper phase containing RNA was transferred 
to a new collection tube. The RNA was then isolated with the help 
of RNeasy Mini spin columns and different buffers according to the 
manufactures’ instructions.
MiR‐screening in all cell types and in all urine samples was 
done with TaqMan® Array Human MicroRNA Card Set v3.0 and 
Megaplex™ RT Primers Human Pool Set v3.0 (Life Technologis, 
Carlsbad, CA). The set enables quantitation of 754 human miRs 
and includes endogenous control for data normalization and one 
TaqMan® MicroRNA Assay not related to human as a negative con‐
trol. Pre‐amplification of miRs before the screening analysis was 
done with Megaplex™ PreAmp Primers, Human Pool Set v3.0 (Life 
Technologis) according to manufactures’ instructions.
2.3 | Data analysis
We	used	the	delta‐delta	cycle	threshold	(CT)	method	to	normalize	our	
miR‐screening data and to generate fold changes in miR‐expression 
after	TGF‐β stimulation and fold changes in miR‐expression in urine 
samples from patients with glomerular diseases compared to control.
Delta‐delta CT = delta CT (sample) – delta CT (reference) with 
delta CT (sample) = CT value for sample normalized to endogenous 
housekeeping gene and delta CT (reference) = CT value for calibra‐
tor normalized to endogenous housekeeping gene. The CT is defined 
as the number of cycles required for the fluorescent signal to cross 
the threshold (ie exceeds background level). CT levels are inversely 
proportional to the amount of target nucleic acid in the sample.
The maximum allowable CT value in our study was set to 35. 
MiR‐samples with bad intensity quality were excluded in the anal‐
ysis. The normalization of the miR‐screening data of the different 
cell	lines	was	done	with	the	housekeeper	U6	snRNA‐001973.	Other	
like	RNU48	or	RNU44	was	not	used	because	they	were	regulated	
in our cell‐screening. This is in line with published data showing 
that	 these	small‐nucleolar	RNAs	 like	RNU44,	RNU48,	RNU43	and	
RNU6B	commonly	used	for	miR‐normalization	are	 regulated	 in	 tu‐
mours.15 The housekeeper for the miR‐analysis in urines was cel‐39 
that was spiked into pooled urines of each disease before miR‐iso‐
lation. Normalized CT values were then transformed into relative 
quantity (RQ) value according to formula 2−(delta‐delta	CT). MiRs with 
RQ values >1.5 were considered up‐regulation and <0.5 were con‐
sidered down‐regulation.
3  | RESULTS
3.1 | MiR‐screening setup
We	 performed	 a	 Q‐PCR	 based	 miR‐screening	 (TaqMan® Array 
Human MicroRNA Card Set v3.0) in cultured human podocytes, 
TA B L E  1   Characteristics of patients from the urinary 
miR‐screening
Disease Age [years] sex
serum 
creatinine 
[μmol/l] UPC ratio [μg/ml]
MGN 81 w 83 5.474
MGN 65 w 103 1.617
MGN 59 m 127 11.352
MGN 30 m 194 10.270
FSGS 18 w 110 5.873
FSGS 32 w 146 19.562
FSGS 47 m 239 1.962
FSGS 42 m 273 5.500
MCD 44 w 60 2.614
MCD 42 w 42 3.660
MCD 25 m 99 6.413
MCD 14 m 73 2.986
DN 52 w 76 1.149
DN 41 w 76 265
DN 67 m 112 1.808
DN 41 m 146 8.920
PEEC 38 w ‐ 5.431
PEEC 35 w ‐ 4.834
PEEC 37 w ‐ 1.371
PEEC 34 w ‐ 1.852
ANCA 60 w 315 2.077
ANCA 50 w 206 608
ANCA 70 m 126 170
ANCA 64 m 150 1.853
IgA‐GN 51 w 78 5.100
IgA‐GN 12 w 42 169
IgA‐GN 44 m 167 2.525
IgA‐GN 49 m 112 862
HUS 75 w
HUS 44 w
HUS 58 m
HUS 40 m
DN,	 diabetic	 nephropathy;	 FSGS,	 focal	 segmental	 glomerulosclerosis;	
HUS,	 haemolytic	 uraemic	 syndrome;	 IgA‐GN,	 IgA‐glomerulonephritis;	
MCD, minimal change disease; MGN, membranous glomerulonephritis; 
MPGN, membranoproliferative glomerulonephritis; PREEC, preeclampsia.
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human glomerular endothelial cells, human mesangial cells and 
human proximal tubular cells in unstimulated conditions and after 
stimulation	with	TGF‐β. The same miR‐screening was performed in 
pooled	urine	samples	from	patients	with	FSGS,	MGN,	MPGN,	DN,	
MCD,	 PREEC,	 HUS,	 IgA‐GN	 and	 healthy	 controls.	 The	 screening	
enabled the detection of 754 different human miRs. A schematic il‐
lustration	of	the	miR‐screening	is	given	in	Figure	1.	Patients’	charac‐
teristics	are	given	in	Table	1.	Urine	samples	of	two	women	and	two	
men (except PREEC: urine samples of four women) with an active 
form of their disease were used for the miR‐screening.
3.2 | Renal cell type‐specific miRs
By comparing the individual expression levels of each miR in the 
different cell types to the mean expression level of this miR in all 
cell types, we were able to detect cell type‐specific miRs (Table S1). 
TA B L E  2   Cell type‐specific miRs in cultured human glomerular endothelial cell, mesangial cells, podocytes and tubular cells
Endothelial cells Mesangial cells Podocytes Tubular cells
hsa‐miR‐1197 hsa‐miR‐1269 hsa‐miR‐106b# hsa‐miR‐499‐3p hsa‐miR‐101#
hsa‐miR‐1291 hsa‐miR‐129# hsa‐miR‐10a hsa‐miR‐502 hsa‐miR‐1262
hsa‐miR‐140‐3p hsa‐miR‐129 hsa‐miR‐10b hsa‐miR‐505# hsa‐miR‐1278
hsa‐miR‐192 hsa‐miR‐138‐2# hsa‐miR‐1180 hsa‐miR‐517a hsa‐miR‐139‐3p
hsa‐miR‐31# hsa‐miR‐141 hsa‐miR‐1201 hsa‐miR‐517c hsa‐miR‐16‐2#
hsa‐miR‐31 hsa‐miR‐196b hsa‐miR‐1292 hsa‐miR‐518e hsa‐miR‐182
hsa‐miR‐337‐3p hsa‐miR‐202 hsa‐miR‐1293 hsa‐miR‐548b hsa‐miR‐182#
hsa‐miR‐337‐5p hsa‐miR‐320 hsa‐miR‐145# hsa‐miR‐548c‐5p hsa‐miR‐183#
hsa‐miR‐339‐3p hsa‐miR‐326 hsa‐miR‐146b hsa‐miR‐548H hsa‐miR‐20b#
hsa‐miR‐34a# hsa‐miR‐449 hsa‐miR‐198 hsa‐miR‐582‐5p hsa‐miR‐296‐3p
hsa‐miR‐411 hsa‐miR‐509‐5p hsa‐miR‐200a hsa‐miR‐584 hsa‐miR‐346
hsa‐miR‐431 hsa‐miR‐517# hsa‐miR‐23a hsa‐miR‐589 hsa‐miR‐363
hsa‐miR‐433 hsa‐miR‐520f hsa‐miR‐26a‐2# hsa‐miR‐604 hsa‐miR‐363#
hsa‐miR‐485‐3p hsa‐miR‐572 hsa‐miR‐302b hsa‐miR‐615‐5p hsa‐miR‐452
hsa‐miR‐539 hsa‐miR‐630 hsa‐miR‐361 hsa‐miR‐629 hsa‐miR‐132#
hsa‐miR‐624 hsa‐miR‐657 hsa‐miR‐130b# hsa‐miR‐369‐5p hsa‐miR‐152
hsa‐miR‐656 hsa‐miR‐674 hsa‐miR‐27b# hsa‐miR‐372 hsa‐miR‐505
hsa‐miR‐770‐5p hsa‐miR‐1263 hsa‐miR‐144 hsa‐miR‐18a# hsa‐miR‐508
hsa‐miR‐938 hsa‐miR‐181a‐2# hsa‐miR‐26a hsa‐miR‐566 hsa‐miR‐520c‐3p
hsa‐miR‐941 hsa‐miR‐494 hsa‐miR‐34b hsa‐miR‐582‐3p hsa‐miR‐551b#
hsa‐miR‐942 hsa‐miR‐509‐3‐5p hsa‐miR‐1228# hsa‐miR‐641 hsa‐miR‐554
hsa‐miR‐130a# hsa‐miR‐556‐5p hsa‐miR‐429 hsa‐miR‐662 hsa‐miR‐561
hsa‐miR‐216a hsa‐miR‐593 hsa‐miR‐432 hsa‐miR‐663B hsa‐miR‐575
hsa‐miR‐543 RNU48 hsa‐miR‐449b hsa‐miR‐720 hsa‐miR‐623
hsa‐miR‐574‐3p hsa‐miR‐191 hsa‐miR‐450b‐3p hsa‐miR‐744# hsa‐miR‐627
hsa‐miR‐629 hsa‐miR‐380‐3p hsa‐miR‐483‐3p hsa‐miR‐758 hsa‐miR‐646
hsa‐miR‐668 hsa‐miR‐672 hsa‐miR‐483‐5p hsa‐miR‐765 hsa‐miR‐649
hsa‐miR‐130a# hsa‐miR‐1274A hsa‐miR‐488 hsa‐miR‐769‐5p hsa‐miR‐651
hsa‐miR‐216a hsa‐miR‐220 hsa‐miR‐489 hsa‐miR‐872 hsa‐miR‐664
hsa‐miR‐543 hsa‐miR‐873 hsa‐miR‐92a‐2#
hsa‐miR‐574‐3p hsa‐miR‐874 hsa‐miR‐92b#
hsa‐miR‐629 hsa‐miR‐876‐3p hsa‐miR‐943
hsa‐miR‐668 hsa‐miR‐876‐5p mmu‐miR‐374‐5p
hsa‐miR‐887 hsa‐miR‐491‐3p
hsa‐miR‐9# hsa‐miR‐500
hsa‐miR‐197
hsa‐miR‐886‐5p
hsa‐miR‐93#
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Thereby, we could identify miR‐143‐3p as podocyte‐specific miR 
that was highly expressed in this cell type (fold change 36 in human 
podocytes compared to 0.37 in human glomerular endothelial cells, 
0.27 in human mesangial cells and 0.25 in human tubular cells). In 
previous experiments we have already documented the importance 
of miR‐143‐3p for podocyte function and ultrastructure.16 Examples 
for glomerular endothelial cell and amesangial cell‐specific miRs 
are miR‐126 and miR‐206, respectively. MiR‐9 was exclusively ex‐
pressed in tubular cells.
We	examined	the	overlap	of	miR‐expression	in	the	different	cell	
types. Twenty‐nine different miRs were only expressed in cultured 
human mesangial cells, 32 miRs were specific for human glomeru‐
lar endothelial cells, 65 miRs were only detectable in human podo‐
cytes and 38 miRs were specific for proximal tubular cells (Table 2). 
Nineteen different miRs could be detected in all four renal cell types 
(Figure	2).
Next, we compared the expression level of each miR and cell type 
to the global mean of all 754 miRs from the screening to categorize 
them in rather high (fold change >10) or low (fold change <0.5), ex‐
pressed (Table S2). This analysis revealed that miR‐126, miR‐126#, 
miR‐531 and mir‐346 were not only glomerular endothelial cell‐specific 
but also highly expressed in this cell type (fold change >10 compared 
to the global mean of all miRs). MiR‐106a# and miR‐302a were highly 
expressed	only	in	mesangial	cells.	Furthermore,	miR‐200b,	miR‐1225,	
miR‐221, miR‐1267 and miR‐331were specific for podocytes and ex‐
pressed more than 10‐fold in this cell type compared to the global 
mean.	Four	different	miRs	were	rather	high	expressed	and	specific	for	
tubular cells: miR‐1305, miR‐499‐3p, let‐7b and miR‐454 (Table S2).
A third way of analysis is comparing the mean miR‐expression 
levels of all cell types to the global mean of miR‐expression level 
of all miRs, Again, we looked for miRs that where only expressed 
more than 10‐fold in one cell type. This method gave rather sim‐
ilar but different results than the data analysis above. MiR‐126, 
miR‐581, miR‐1274A and miR‐126# were endothelial cell‐specific 
whereas miR‐106a#, miR‐484 and let 7b were specific for mesangial 
cell.	For	podocytes	the	same	miRs	as	in	the	analysis	above	came	up:	
miR‐200b, miR‐1225, miR‐221, miR‐1267 and miR‐331. MiR‐1305, 
miR‐520b and miR‐486 were only up‐regulated in tubular cells more 
than 10‐fold (Table S3).
3.3 | MiRs regulated by TGF‐β in cultured renal cells
To identify cell stress inducible miRs we compared miR‐profiles from 
cultured	renal	cell	lines	before	and	after	stimulation	with	TGF‐β.	We	
generated	fold	changes	in	miR‐expression	levels	after	TGF‐β stimu‐
lation (Table S4) and looked at the context cell type‐specific up‐ or 
down‐regulation	of	miRs.	Figure	3A‐D	gives	the	number	of	miRs	up‐
regulated (fold change >1.5, red), down‐regulated (fold change <0.5, 
green) or unregulated (fold change >0.5 and <1.5, overlap) after stim‐
ulation	with	TGF‐β	in	human	mesangial	cells	(Figure	3A),	human	glo‐
merular	endothelial	cells	 (Figure	3B),	human	podocytes	 (Figure	3C)	
and	human	tubular	cells	(Figure	3D).
Of note, most miRs were down‐regulated following the stimu‐
lation	with	TGF‐β	 in	all	cell	types.	Up‐regulation	of	miR‐expression	
after	 stimulation	with	TGF‐β was most prominent in cultured glo‐
merular endothelial cells and podocytes. Moreover, up‐regulation of 
miRs	after	TGF‐β	was	cell	type‐specific	for	most	miRs.	For	example,	
miR‐378a‐3p was specifically up‐regulated in cultured human podo‐
cytes.	We	previously	described	the	importance	of	miR‐378a‐3p	for	
glomerular filter function and ultrastructure.17
Interestingly, the regulation of some miRs was concordant for 
more	 than	 one	 cell	 type.	 For	 example,	miR‐199a‐3p	was	 up‐regu‐
lated in both mesangial cells and podocytes. MiR‐1247 was up‐reg‐
ulated not only in podocytes but also in tubular cells. MiR‐1243, 
miR‐1225‐3p, miR‐520D‐3p and miR‐520c‐3p were induced after 
stimulation	 with	 TGF‐β in glomerular endothelial cells as well as 
tubular cells. This suggests that these cell types regulate common 
pathways. It is striking that we found no miR significantly up‐regu‐
lated in more than two cell types, indicating that the miR‐regulation 
after	TGF‐β is clearly cell type‐specific.
3.4 | MiRs in cell‐free urines from patients with 
different glomerular diseases compared to control
Next, we examined in a screening experiment urinary miR‐profiles 
from pooled urine samples from patients with different glomerular 
diseases and compared them to those from healthy controls (Table 
S5). Interestingly, except for ANCA and IgA‐GN, most miRs were 
higher	 expressed	 in	 disease	urines	 compared	 to	 controls.	 Figure	4	
gives the number of miRs up‐regulated (fold change >1.5, red), down‐
regulated (fold change <0.5, green) or unregulated (fold change >0.5 
and	<1.5,	overlap)	 in	MGN	(Figure	4A),	PREEC	(Figure	4B),	 IgA‐GN	
(Figure	4C),	 DN	 (Figure	4D),	 FSGS	 (Figure	4E),	 MCD	 (Figure	4F),	
ANCA	(Figure	4G)	and	HUS	(Figure	4H).
The 10 top up‐regulated and 10 top down‐regulated miRs in the 
urines from patients compared to healthy controls are depicted in 
the	charts	of	Figure	4A‐H.	Only	one	miR	was	up‐regulated	in	all	dis‐
ease urines compared to control. This was miR‐155.
F I G U R E  2   MiR‐screening in different cultured renal cell types. 
Venn	diagram	shows	miRs	found	in	different	un‐stimulated	cultured	
renal cells with the TaqMan® Array based miR‐screening. The 
different	colours	in	the	Venn	result	from	overlapping	miRs	in	the	
different cell types. Number of miRs only found in one cell type 
(fields at the extreme end of the venn diagrams) or expressed in 
different cell types are indicated in the corresponding fields
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MiR‐155 also caught our attention in the miR‐screening in the 
cells. It was much higher expressed in glomerular endothelial cells 
compared to other cell types (fold change 9.0, Table S1). It consis‐
tently was detected in high fold change in glomerular endothelial 
cells (miR‐expression analysis with the global mean of all miRs and 
miR‐expression analysis with the local mean of all miRs; Tables S2 
and	S3).	After	stimulation	with	TGF‐β miR‐155 was further up‐regu‐
lated in glomerular endothelial cells (fold change 5.4, Table S4).
We	were	able	 to	 identify	disease‐specific	miRs	 that	were	only	
detectable in one glomerular disease and not present in controls. 
These disease‐specific miRs were let‐7 g for MGN, miR‐99b# for 
PREEC,	miR‐603	for	FSGS	and	miR‐590	for	ANCA.
F I G U R E  3  MiRs	regulated	by	TGF‐β 
in different cultured renal cell types. 
Venn	diagrams	depict	the	number	of	
miRs up‐regulated (fold change >1.5, red), 
down‐regulated (fold change <0.5, green) 
or unregulated (fold change >0.5 and <1.5, 
overlap)	after	TGF‐β in cultured human 
mesangial cells (A), human glomerular 
endothelial cells (B), human podocytes (C) 
and human tubular cells (D). Charts give 
the fold change in miR‐expression of the 
top 10 up‐regulated (black bars) and top 
10 down‐regulated miRs after stimulation 
with	TGF‐β compared to untreated 
condition
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3.5 | Assigning urinary miRs to the different renal 
cell types
By combining the cell and urinary miR‐screenings, we could assign 
the miRs found in the urines from patients with glomerular dis‐
eases	 to	 the	miRs	 identified	 in	TGF‐β stressed cultured renal cells 
(Figure	5A‐H).	 The	 combination	 of	 cell	 and	 urine	 miR‐screenings	
enabled us to identify cell type‐specific miRs in the different glo‐
merular	diseases	(Table	3	and	Figure	5A‐H).
4  | DISCUSSION
It is estimated that 60% of the total human proteome is regulated by 
about 2000 known miRs.18 MiRs also seem to play an important role 
in gene regulation in disease processes.
Therefore, miR‐screenings are novel tools to find diagnostic 
markers or even therapeutic targets in glomerular diseases. In the 
past, miR‐screenings were predominantly performed in serum or 
urine from patients. However, by analysing miRs in body fluids only 
TA B L E  3   Cell type‐specific miRs in the different glomerular diseases
MGN + ENDO MGN + ENDO MGN + PODOS MGN	+	TUBULUS
hsa‐miR‐192‐000491 hsa‐miR‐1274A‐002883 hsa‐miR‐10a‐000387 hsa‐miR‐152‐000475
hsa‐miR‐200c‐002300 hsa‐miR‐141‐000463 hsa‐miR‐10b‐002218 hsa‐miR‐197‐000497
hsa‐miR‐31‐002279 hsa‐miR‐191‐002299 hsa‐miR‐146b‐001097 hsa‐miR‐886‐5p‐002193
hsa‐miR‐574‐3p‐002349 hsa‐miR‐320‐002277 hsa‐miR‐200a‐000502 hsa‐miR‐93#‐002139
hsa‐miR‐26a‐000405 hsa‐miR‐99b‐000436
hsa‐miR‐429‐001024
hsa‐miR‐720‐002895
hsa‐miR‐99b‐000436
FSGS + ENDO FSGS + MESANG FSGS + PODOS FSGS + TUBULUS
hsa‐miR‐200c‐002300 hsa‐miR‐141‐000463 hsa‐miR‐10a‐000387 hsa‐miR‐886‐5p‐002193
hsa‐miR‐31‐002279 hsa‐miR‐320‐002277 hsa‐miR‐146b‐001097
hsa‐miR‐26a‐000405
hsa‐miR‐720‐002895
IgA‐GN + ENDO IgA‐GN + MESANG IgA‐GN + PODOS IgA‐GN + TUBULUS
hsa‐miR‐200c‐002300 hsa‐miR‐1274A‐002883 hsa‐miR‐10a‐000387 hsa‐miR‐197‐000497
hsa‐miR‐141‐000463 hsa‐miR‐10b‐002218 hsa‐miR‐93#‐002139
hsa‐miR‐200a‐000502
hsa‐miR‐26a‐000405
hsa‐miR‐489‐002358
hsa‐miR‐720‐002895
DN + ENDO DN + MESANG DN + PODOS DN + TUBULUS
hsa‐miR‐200c‐002300 hsa‐miR‐1274A‐002883 hsa‐miR‐26a‐000405 hsa‐miR‐152‐000475
hsa‐miR‐31‐002279 hsa‐miR‐191‐002299 hsa‐miR‐720‐002895 hsa‐miR‐93#‐002139
hsa‐miR‐574‐3p‐002349 hsa‐miR‐320‐002277
MCD + ENDO MCD + MESANG MCD + PODOS MCD + TUBULUS
hsa‐miR‐200c‐002300 hsa‐miR‐191‐002299 hsa‐miR‐10a‐000387 hsa‐miR‐93#‐002139
hsa‐miR‐574‐3p‐002349 hsa‐miR‐10b‐002218
hsa‐miR‐146b‐001097
hsa‐miR‐720‐002895
HUS + ENDO HUS + MESANG HUS + PODOS HUS + TUBULUS
hsa‐miR‐31‐002279 hsa‐miR‐1274A‐002883 hsa‐miR‐10a‐000387 hsa‐miR‐886‐5p‐002193
hsa‐miR‐191‐00229 hsa‐miR‐10b‐002218
hsa‐miR‐200a‐000502
hsa‐miR‐26a‐000405
hsa‐miR‐489‐002358
(Continues)
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(Table S5), the origin of the miRs as well as their pathophysiological 
role	in	disease	remains	elusive.	Urinary	miRs	might	be	filtered	or	ex‐
creted by the kidney. Alternatively they might be directly derived 
from renal cells during the disease process.
We	performed	three	different	miR‐screenings	with	745	different	
miRs: One in different renal cell types under normal culture condi‐
tion,	 one	 in	 cultured	 renal	 cell	 types	 after	 stimulation	with	TGF‐β 
and another in urine samples from patients with different glomerular 
diseases. These data are the basis for different ways of analysis de‐
pending on the biological question to be answered.
Most studies on urinary miRs used the urine sediment obtained 
after low‐speed centrifugation. However, a large number of low‐
quality and degraded RNA was recently detected in the urinary cell 
pellet.19 Therefore, we decided to use the cell‐free supernatants 
of	pooled	patient	urines	 in	our	miR‐screening.	We	 first	wanted	 to	
identify	potentially	cell	type‐specific	miRs.	We	could	find	miR‐126	as	
one of the glomerular endothelial cell‐specific miRs in our screening. 
Well	 in	 line	with	this	finding,	miR‐126	was	already	described	as	an	
endothelial cell‐specific miR that governs vascular integrity in other 
tissue.20‐23
MiR‐143‐3p was predominantly expressed in podocytes in our 
miR‐screening.	We	have	confirmed	the	 importance	of	 this	miR	 for	
the maintenance of a functional glomerular filtration barrier in the 
zebrafish model.16 MiR‐30 family members were also highly ex‐
pressed in our cultured human podocytes. In line with this, a role 
of the miR‐30 family in podocyte homeostasis was previously de‐
scribed in mice.24
The comparison of cellular miR‐profiles before and after stim‐
ulation	 with	 TGF‐β revealed cell stress‐induced miRs. Most miRs 
up‐regulated	after	TGF‐β were cell type‐specific and none was reg‐
ulated in more than two renal cell types. Some cell type‐specific 
regulations	 were	 consistent	 with	 previous	 findings.	 For	 example,	
miR‐143‐3p	and	miR‐378a‐3p	are	known	to	be	regulated	by	TGF‐β 
in non‐renal cells.25,26 Both miRs were also up‐regulated in cultured 
human	podocytes	after	stimulation	with	TGF‐β in our miR‐screen‐
ing. Circulating miR‐210 predicts survival in critically ill patients with 
acute kidney injury.27 Interestingly, miR‐210 was up‐regulated after 
TGF‐β in human mesangial cells in our study. MiR‐199a‐3p was up‐
regulated in human mesangial cells and podocytes after stimulation 
with	 TGF‐β. A known target of miR‐199a‐3p is versican also pro‐
duced by podocytes and mesangial cells.28,29
Most miRs were down‐regulated following the stimulation 
with	TGF‐β in our miR‐screening in cultured human renal cell lines. 
TGF‐β is associated with the increase in many pro‐fibrotic and 
inflammatory	 markers.	 MiRs	 down‐regulation	 after	 TGF‐β might 
contribute	 to	 this	 increase	 in	 target	expression	 levels.	For	exam‐
ple depletion of renal miR‐196a/b by miR‐196a/b antagomirs sub‐
stantially aggravated unilateral ureteral obstruction‐induced renal 
fibrosis.30 During renal injury, reduction in miR‐29a and miR‐29b 
enhances collagen expression31 and down‐regulation of miR‐200a 
expression	 promotes	 TGF‐dependent	 epithelial‐to‐mesenchymal	
transition.32
The miRs down‐regulated in our cultured renal cell lines after 
stimulation	with	TGF‐β may give cues to look for interesting up‐reg‐
ulated	targets	to	prove	TGF‐β mediated fibroses and inflammation 
regulated	through	miRs.	Elevating	miRs	that	are	decreased	by	TGF‐β 
by miR‐mimics might have therapeutically potential.
Regarding the urinary miR‐screening, most miRs were higher 
expressed in patients with glomerular diseases compared to 
healthy controls. This might be due to the increased leakiness of 
the glomerular filtration barrier in glomerular disease that also 
allows more micro particles and RNA‐binding proteins associ‐
ated with miRs to pass.33 Recently, urinary miR‐21, miR‐200c and 
miR‐423 have been identified as sensitive indicators of kidney in‐
jury. MiR‐21 was also described to inhibit pathophysiological path‐
ways in DN.34
MGN + ENDO MGN + ENDO MGN + PODOS MGN	+	TUBULUS
hsa‐miR‐720‐002895
PREE + ENDO PREE + MESANG PREE + PODOS PREE + TUBULUS
hsa‐miR‐200c‐002300 hsa‐miR‐1274A‐002883 hsa‐miR‐10a‐000387 hsa‐miR‐152‐000475
hsa‐miR‐31‐002279 hsa‐miR‐191‐002299 hsa‐miR‐10b‐002218 hsa‐miR‐197‐000497
hsa‐miR‐574‐3p‐002349 hsa‐miR‐320‐002277 hsa‐miR‐146b‐001097 hsa‐miR‐93#‐002139
hsa‐miR‐26a‐000405
hsa‐miR‐429‐001024
hsa‐miR‐489‐002358
hsa‐miR‐720‐002895
ANCA + ENDO ANCA + MESAG ANCA + PODO ANCA + TUBULUS
hsa‐miR‐192‐000491 hsa‐miR‐1274A‐002883 hsa‐miR‐200a‐000502 hsa‐miR‐197‐000497
hsa‐miR‐320‐002277 hsa‐miR‐26a‐000405 hsa‐miR‐93#‐002139
hsa‐miR‐429‐001024
hsa‐miR‐489‐002358
TA B L E  3   (Continued)
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Nevertheless, the origin of these urinary miRs is unknown.35 
In our screening, miR‐21 was expressed in cultured human me‐
sangial cells and podocytes and was detectable as up‐regulated 
in	urines	from	patients	with	IgA‐GN,	FSGS,	MCD,	MGN,	PREEC	
and DN.
In animal models of kidney injury, miR‐21 expression was found 
to be increased as well. However, its function remains controversial, 
because it has been implicated in promotion as well as protection 
from tubule‐interstitial and glomerular injury.36‐39
MiR‐21	was	described	to	ameliorate	TGF‐β and hyperglycemia‐
induced glomerular injury through repression of pro‐apoptotic 
signals.34 In contrast to this, murine models of tubule‐intersti‐
tial kidney injury demonstrated that miR‐21 contributes to fi‐
brogenesis and epithelial injury.36 In line with these findings, 
miR‐21 antagonism rescued mesangial expansion, interstitial fi‐
brosis, macrophage infiltration, podocyte loss, albuminuria and 
fibrotic‐ and inflammatory gene expression in mice with diabetic 
nephropathy.40
F I G U R E  4   MiRs expressed in urines 
from patients with different glomerular 
diseases	compared	to	control.	Venn	
diagrams give the number of miRs 
up‐regulated (fold change >1.5, red), 
down‐regulated (fold change <0.5, green) 
or un‐regulated (fold change >0.5 and 
<1.5, overlap) in pooled urine samples 
from patients with MGN (A), PREEC 
(B),	IgA‐GN	(C),	DN	(D),	FSGS	(E),	MCD	
(F),	ANCA	(G)	and	HUS	(H)	compared	
to pooled urines from healthy controls. 
Charts give the fold change in miR‐
expression of the top 10 up‐regulated 
(black bars) and top 10 down‐regulated 
miRs in urines samples from patients with 
glomerular diseases compared to control. 
Abbreviations: DN, diabetic nephropathy; 
FSGS,	focal	segmental	glomerulosclerosis;	
HUS,	haemolytic	uraemic	syndrome;	
IgA‐GN, IgA‐glomerulonephritis; 
MCD, minimal change disease; MGN, 
membranous glomerulonephritis; 
MPGN, membranoproliferative 
glomerulonephritis; PREEC, preeclampsia
3936  |     MÜLLER‐DEILE Et aL.
In another study of diabetic kidney disease, miR‐21 enhanced 
high glucose‐induced TOR complex 1 activity, resulting in renal cell 
hypertrophy and fibronectin expression.39
Our findings and data from the literature suggest that miR‐21 
might have diverse functions in different glomerular disease con‐
texts and its regulation might be much more complex than initially 
suggested.
MiR‐378a‐3p was found in urines samples from patients with 
MGN,	FSGS	and	MCD	and	up‐regulated	in	cultured	human	podocytes	
in	response	to	TGF‐β treatment. In a previous study we could confirm 
the importance of miR‐378a‐3p for glomerular function as it is a regu‐
lator of the glomerular matrix protein nephronectin.17 Thus, our data 
confirm that urinary miRs seem to be markers for renal injury.
MiR‐155 was the only miR that was up‐regulated in all disease 
urines compared to control. In all different analysis strategies in cells 
including	 the	analysis	after	TGF‐β‐stimulation, miR‐155 was highly 
up‐regulated	 in	 glomerular	 endothelial	 cells.	 TGF‐β‐regulation of 
miR‐155 has been described before.41	Well	in	line	with	our	observa‐
tion miR‐155 was previously described by others to play an import‐
ant role in endothelial cell activation.42,43
F I G U R E  4   (Contiunued)
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Patients with diabetic nephropathy displayed reduced levels of 
serum miR‐31. Moreover, miR‐31 levels were positively correlated 
with leucocyte rolling velocity and negatively associated to leuco‐
cyte	adhesion,	TNFα, IL‐6 and ICAM‐1 levels.44	We	did	not	found	
miR‐31 among the top 10 miRs down‐regulated in diabetic nephrop‐
athy compared to control in our miR‐screening. This highlights the 
importance of the type of bio‐fluid investigated in miR‐studies.
Overexpression of miR‐370 was shown to promote mesangial 
cell proliferation and extracellular matrix accumulation by suppress‐
ing CNPY1 in a rat model of diabetic nephropathy. However, this miR 
was not among the top 10 miRs regulated in human renal cells or 
urines from patients. This indicated that a species‐specific miR‐anal‐
ysis seems to be important as there might be differences in miR‐ex‐
pression in humans and rats.45
Combining the cellular and urinary miR‐screening, we were able 
to define disease‐specific and cell type‐specific miR‐profiles and 
could assign the urinary miRs to the different renal cell types. To 
our knowledge this is the first study merging biological samples from 
patients with results from unstressed and stressed cultured cells to 
identify biological important miRs. Even though our screening aimed 
to identify miRs relevant in the pathology we confirmed several 
published previous observations by us and others. A limitation of 
our study is that the screening results have to be confirmed in in‐
dependent experiments or larger patient cohorts. Nevertheless our 
approach uses a unique comparison in eight different disease groups 
and all corresponding glomerular cell types and is therefore a first 
approach to identify novel miRs potentially involved in the patho‐
physiology of glomerular diseases.
F I G U R E  5  Merged	results	from	urinary	miRs	of	patients	with	different	glomerular	diseases	and	the	renal	cell	types.	Venn	diagram	
depicts	the	miRs	expressed	in	urine	samples	from	patients	with	MGN	(A),	PREEC	(B),	IgA‐GN	(C),	DN	(D),	FSGS	(E),	MCD	(F),	ANCA	(G)	
and	HUS	(H)	to	GECs,	MCs,	PODs	and	TCs.	The	different	colours	in	the	venn	result	from	overlapping	miRs	in	the	different	cell	types.	
Number of miRs only found in one cell type (fields at the extreme end of the venn diagrams) or expressed in different cell types are 
indicated	in	the	corresponding	fields.	Abbreviations:	DN,	diabetic	nephropathy;	GECS,	glomerular	endothelial	cells;	FSGS,	focal	segmental	
glomerulosclerosis;	HUS,	haemolytic	uraemic	syndrome;	IgA‐GN,	IgA‐glomerulonephritis;	MCD,	minimal	change	disease;	MGN,	membranous	
glomerulonephritis; MPGN, membranoproliferative glomerulonephritis; MCS, mesangial cells; PEEC, preeclampsia; PODS, podocytes; TCS, 
tubular cells
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